Abstract
In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for AHC, 9% (3/34) for DBD, and 14% (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Comis RL: DTIC in malignant melanoma: A perspective. Cancer Treat Rep 60:165–176, 1976
Carbone PP, Costello W: Eastern Cooperative Oncolgy Group studies with DTIC (NSC-45388). Cancer Treat Rep 60:193–198, 1976
Ahmann DL: Nitrosoureas in the management of disseminated malignant melanoma. Cancer Treat Rep 60:747–751, 1976
Luce JK: Chemotherapy of malignant melanoma. Cancer 30:1604–1615, 1972
Carter SK, Friedman MA: 5(3,3 Dimethyl-1-triazeno)-immidazole-4-carboxamide (DTIC, DIC, NSC-45388) — a new antitumor agent with activity against malignant melanoma. Eur J Cancer 8:85–92, 1972
Benjamin RS: Chemotherapy of malignant melanoma. World J Surg 3:321–328, 1979
Comis RL, Carter SK: Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev 1:285–304, 1974
Costanza ME, Nathanson L, Schoenfeld D, Wolter J, Colsky J, Regelson W, Cunningham T, Sedransk N: Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 40:1010–1015, 1977
Von Hoff DD, Amato DA, Kaufman JH, Falkson G, Cunningham TJ:, Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma. Am J Clin Oncol (CCT) 7:135–139, 1984
Livingston RB, Carter SK: Single agents in cancer chemotherapy. Plenum Press, New York, 1970
Csányi E, Halàsz M: Cross-resistance studies on 1,6-dibromo-dideoxy-D-mannitol (DBM)-resistant Yoshida S.C. sarcoma. Brit J Cancer 21:353–357, 1967
Mischler NE, Earhart RH, Carr B, Tormey DC: Dibromodulcitol. Cancer Treat Rev 8:191–204, 1979
Belej MA, Troetel WM, Weiss AJ, Stambaugh JE, Manthei RW: The absorption and metabolism of dibromodulcitol in patients with advanced cancer. Clin Pharmacol Ther 13:563–572, 1972
Andrews NC, Weiss AJ, Ansfield FJ, Rochlin DB, Mason JH: Phase I study of dibromodulcitol (NSC-104800). Cancer Chemother Rep 55:61–65, 1971
Andrews NC, Wiess AJ, Wilson W, Nealon T: Phase II study of dibromodulcitol (NCS-104800), Cancer Chemother Rep 58:653–660, 1974
Phillips RW, Brook J: Clinical experiences with dibromodulcitol (NCS-104800) in solid tumors. Cancer Chemother Rep 55:567–573, 1971
Bellet RE, Catalano RB, Mastrangelo MJ, Berd D: Positive phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and a nitrosourea. Cancer Treat Rep 62:2095–2099, 1978
Medina W, Kirkwood JM: Phase II trial of mitolactol in patients with metastatic melanoma. Cancer Treat Rep 66:195–196, 1982
Maiden LT, Coates AS, Milton GW, McCarthy WH, Levi JA, Woods RL, Byrne MJ, Reynolds PM, Fox RM, Hedley DW, Raghavan D, Tattersall MHN: Mitolactol chemotherapy for malignant melanoma: a phase II study. Cancer Treat Rep 68:1045–1046, 1984
Zelen M: The randomization and stratification of patients to clinical trials. J Chron Dis 27:365–375, 1974
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (CCT) 5:649–655, 1982
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481, 1958
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Amato, D.A., Bruckner, H., Guerry, D. et al. Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma. Invest New Drugs 5, 293–297 (1987). https://doi.org/10.1007/BF00175301
Issue Date:
DOI: https://doi.org/10.1007/BF00175301